Marco Valgimigli

Clinical Management of Myocardial Infarction

Despite notable advancements in the acute and long-term management, coronary artery disease and myocardial infarction (MI) remain the leading cause of mortality worldwide. Atherothrombosis overlying coronary plaque rupture or erosion is the main pathophysiological mechanism of MI...

Antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation: an individual patient data network meta-analysis

BACKGROUND AND AIMS: Randomized trials demonstrated that in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) direct oral anticoagulants (DOAC) and a P2Y12 inhibitor reduce bleeding compared with vitamin K antagonist (VKA) plus dual antipl...

Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event

BackgroundPatients are at increased risk for recurrent ischemic events after an acute coronary syndrome event. Milvexian, an oral factor XIa inhibitor, may reduce the risk of major adverse clinical events with minimal bleeding risk. MethodsIn this phase 3, randomized, placebo-con...